A majority of patients undergoing hematopoietic stem cell transplantation (HSCT) suffer from severe mucositis and enteritis due to cytotoxic therapy and immune dysregulation, resulting in prolonged decreased oral intake, nausea, vomiting and diarrhea. While total parenteral nutrition (TPN) is often given to patients in order to maintain their nutritional status during the peritransplant period, there is conflicting evidence to support its routine use. We evaluated the small number of prospective randomized and nonrandomized controlled trials that assessed important clinical outcomes such as time to engraftment, rates of infection, overall survival and length of hospitalization. We believe that the data do not support the routine use of parenteral nutrition as first-line therapy but should be reserved for those patients who are unable to tolerate enteral feedings. We also believe that glutamine supplementation cannot be recommended to all HSCT recipients as it has been shown to increase morbidity and mortality rates in autologous transplant patients. Further investigations that test accurate monitoring assessments and incorporate specific substrates such as lipids with parenteral and enteral nutrition are warranted. Novel therapies such as recombinant human keratinocyte growth factor and glucagon-like peptide show future promise in modulating the severity and duration of mucositis, minimizing further the need for TPN. Bone Marrow Transplantation (2005) 36, 281-288.
A majority of patients undergoing hematopoietic stem cell transplantation (HSCT) suffer from severe mucositis and enteritis due to cytotoxic therapy and immune dysregulation, resulting in prolonged decreased oral intake, nausea, vomiting and diarrhea. While total parenteral nutrition (TPN) is often given to patients in order to maintain their nutritional status during the peritransplant period, there is conflicting evidence to support its routine use. We evaluated the small number of prospective randomized and nonrandomized controlled trials that assessed important clinical outcomes such as time to engraftment, rates of infection, overall survival and length of hospitalization. We believe that the data do not support the routine use of parenteral nutrition as first-line therapy but should be reserved for those patients who are unable to tolerate enteral feedings. We also believe that glutamine supplementation cannot be recommended to all HSCT recipients as it has been shown to increase morbidity and mortality rates in autologous transplant patients. Further investigations that test accurate monitoring assessments and incorporate specific substrates such as lipids with parenteral and enteral nutrition are warranted. Novel therapies such as recombinant human keratinocyte growth factor and glucagon-like peptide show future promise in modulating the severity and duration of mucositis, minimizing further the need for TPN. Since it was first introduced nearly 40 years ago hematopoietic stem cell transplantation (HSCT) has been used to cure a variety of malignant and nonmalignant diseases. While this modality may be a life-saving treatment for many patients, the cytotoxic regimens and the development of graft-versus-host disease (GVHD) often result in significant morbidity. 1 Toxicity to the rapidly dividing cells of the gastrointestinal tract manifests as severe mucositis and enteritis that causes painful oral ulcerations, decreased oral intake, nausea, vomiting and diarrhea. Regardless of nutritional status prior to transplant a majority of patients require nutritional supplementation during the peritransplant period. Total parenteral nutrition (TPN) can be an attractive alternative to enteral feedings in the setting of decreased gut function. Since Weisdorf et al 2 showed an increase in overall survival in adult and pediatric allogeneic and autologous stem cell transplant patients who received TPN, this adjunctive therapy has been considered a standard of care at many transplant centers.
Limitations of TPN
TPN is a treatment potentially associated with significant limitations including a fluid overload state, hyperglycemia and hepatic dysfunction (Table 1) . While some articles that were reviewed stated that there were no statistically significant increases in complications related to TPN, others reported trends towards more bacteremia, cathetersite infections, increased diuretic use and subclavian vein thromboses in those patients who received TPN support. 3 HSCT is a rapidly changing field and the available data on the use of TPN appear to be outdated. The purpose of this review is to present the small number of prospective, randomized and nonrandomized controlled trials of TPN, review their limitations in the setting of current trends and provide insight into new preparations. This review also will present current data on glutamine, lipids and palifermin as well as monitoring techniques in the care of transplant patients.
Methods
Pertinent English language publications were identified by searching PubMed using the keywords, alone or in combination, 'parenteral nutrition', 'glutamine', 'lipids', 'bone marrow transplantation', 'HSCT', 'anthropomorphic parameters', 'nutritional indices' and 'growth factor support.' Our research encompassed the years 1980 through 2004. Additional publications were identified using the reference lists of relevant papers. (Table 2) Reviewed studies employed a variety of variables to assess nutritional states. Although the biochemical or serologic markers are easiest to measure, these tests are influenced significantly by many clinical events, in addition to nutritional states. [4] [5] [6] The most accurate methods such as nitrogen balance and bioelectric impedance measurements are tedious and impractical in the transplant setting, and may require special expertise.
Results
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Review of selected studies (Table 3) Nearly 20 years ago Weisdorf et al 2 performed a prospective, randomized controlled trial comparing TPN to an enriched dextrose solution in 137 adult and pediatric patients ages, 2-45 years, undergoing allogeneic or autologous HSCT for a variety of hematologic and metabolic derangements. Parenteral nutrition was started 7 days before stem cell infusion while the patients were receiving cytoreductive chemotherapy. A composite nutritional status score was calculated weekly for 5 weeks using serum albumin, prealbumin and transferrin concentrations, patient weight, triceps skin-fold thickness and arm muscle circumference. Clinical outcome parameters included overall survival, relapse rate, time to engraftment, disease-free survival, acute and chronic GVHD, bacteremia and duration of hospitalization. The 2-year overall survival and relapse-free survival were significantly longer in those patients receiving TPN (50 vs 35%, P ¼ 0.011 and 41 vs 22%, P ¼ 0.026, respectively). Autograft patients, however, did not show a difference in either category when analyzed separately. Allograft patients who received TPN had a significantly higher rate of bacteremia than the control group (72 vs 48%, P ¼ 0.001). Although caloric and protein intake and serum prealbumin concentrations were significantly higher in the group randomized to TPN, there were no differences in time to engraftment, duration of hospitalization or incidence of GVHD. In all, 61% of those patients randomized to the control arm required TPN due to malnutrition according to their nutritional status score. The authors concluded that the increased overall long-term survival in those patients who received TPN was either due to enhanced chemotherapeutic activity or to improved immune function and marrow recovery with the infusion of nutritional substrates.
That same year, Szeluga et al 3 conducted a smaller study (N ¼ 61) evaluating an individualized enteral feeding program (EFP) as compared to TPN starting the day prior to HSCT in allogeneic or autologous HSCT recipients with hematologic and solid tumors ranging from 10 to 58 years of age. Patients assigned to the EFP group were allowed oral intake ad libitum, supplemented with high-protein snacks or i.v. amino acids in cases of poor protein intake. If their oral intake remained below the minimum nutrient goals for at least 10 days, they were eligible for nasogastric tube feeding. Seven patients (23% of the EFP participants) were eventually deemed EFP failures; nasogastric tube feeding was attempted in a majority of those patients prior Table 1 Advantages and disadvantages of total parenteral nutrition
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High to initiation of TPN but was terminated because of nausea, vomiting or compliance. While patients receiving TPN had higher total energy and protein intake than those on an EFP, there were no differences in survival, hematologic recovery, duration of stay, GVHD or infection rates. There were no complications associated with the use of nasogastric tubes. The TPN group trended towards more catheterrelated complications such as bacteremia, catheter-site infections and subclavian vein thromboses, but this was not a statistically significant increase. Those patients randomized to receive TPN also required more diuretics for fluid overload (11 vs 6 days of use, P ¼ 0.0001). Subjects also had more days of hyperglycemia (9 vs 2 days, P ¼ 0.0002) and fewer days of hypomagnesemia than their EFP counterparts (6 vs 15 days, Po0.0001). The mean cost per patient for TPN support was more than two times the cost of enteral nutritional support, $2575/TPN patient vs $1139/EFP patient. While the authors cautioned that the EFP required intensive nutritional counseling, they stated that TPN should be reserved for those patients who fail ad libitum oral intake and nasogastric tube feedings. Mulder et al 10 compared TPN with partial parenteral nutrition (PPN) and enteral tube feedings commencing three days prior to transplantation in 22 autologous HSCT solid tumor patients ranging from 21 to 56 years of age. The lipid-free PPN formula contained two-thirds the amount of glucose and one-half the amount of protein as compared to the TPN regimen. There were no treatmentrelated differences in various parameters such as serum total protein, albumin, transferrin and prealbumin concentrations. Further, there were no differences in time to engraftment, days of fever or length of hospital stay.
Patients who received TPN maintained their weight-height indices (WHI) unlike their PPN counterparts (nadir WHI 110.1 vs 90.7, Po0.001). Patients randomized to the PPN and enteral feeding arm had fewer days of diarrhea (53.6 vs 26.8 days, Po0.005) and had twice as many positive blood cultures although the latter was not statistically significant. The authors postulated that mucositis and nasogastric tube feeding could promote bacterial invasion across the gastrointestinal tract but concluded that in autologous HSCT patients, PPN and enteral feedings appear to be an alternative to TPN.
Charuhas et al 11 evaluated the effect of parenteral nutrition on resumption of oral intake after autologous, allogeneic or syngeneic HSCT for hematologic and solid tumors. In all, 258 patients from 2 to 64 years of age were randomized to receive a 5% dextrose solution or TPN until they were able to consume at least 85% of estimated energy requirements for three consecutive days. The primary endpoint was time to resumption of oral intake; other study endpoints were readmission to the hospital, weight change, relapse and survival. Patients randomized to TPN resumed complete oral intake six days later than the hydration group, regardless of fluid volumes received (median of 10 vs 16 days, P ¼ 0.049). Although the hydration group lost more weight than their TPN counterparts (4.63% loss vs 1.27% loss, P ¼ 0.004), there were no differences in readmission to the hospital, relapse or survival. The authors cited similar studies which demonstrate that amino-acid infusions delay oral intake in other patient populations. [12] [13] [14] The mechanisms of these interactions are not well understood. These investigators recommended that TPN not be given routinely upon discharge /l did not differ between the two groups, those patients randomized to received TPN had a significantly longer mean time to platelet engraftment (15.5 vs 12.9 days, P ¼ 0.014). This difference was also seen when TPN patients were compared to only those PPN patients who received granulocytemacrophage colony-stimulating factor (15.5 vs 12.6 days, P ¼ 0.017). Accordingly, patients who received TPN required more platelet transfusions (1.93 vs 1.16 units, P ¼ 0.004) without a difference in red blood cell transfusion requirements or duration of hospital stay. Patients in the TPN group had a greater number of positive blood cultures (64.5 vs 40%, P ¼ 0.05) without more antibiotic use or febrile days. They also had higher concentrations of blood glucose and urea than the PPN group (159 vs 136 mg/dl, P ¼ 0.03 and 34 vs 27 mg/dl, Po0.001, respectively). Patients who received TPN maintained their albumin levels during the peritransplant period, but neither group maintained body mass index nor body weight. The authors could not explain the differences in platelet engraftment in this patient population, and this effect was not observed in any other studies that we reviewed.
In a small, prospective, randomized controlled trial, Lough et al 16 compared TPN or a 5% dextrose solution using biochemical and anthropomorphic measurements on the outcomes of rates of infectious complications, days of fever, weight loss, time to engraftment and survival in 29 adult autologous and allogeneic HSCT patients with hematologic malignancies. TPN had to be discontinued in seven of 14 patients due to fluid overload. The group randomized to the TPN arm had significantly more days of fever (3 vs 1 day, Po0.05) and a greater number of patients in the TPN group had positive blood cultures as compared to those patients who received only maintenance fluids (eight patients vs one patient, Po0.05). Median serum bilirubin and gamma glutamyl transferase levels were higher in the TPN group (20.5 vs 16 mmol/l and 47.5 vs 33.0 units/l, respectively, with both Po0.05). Median serum retinol binding protein, transferrin and albumin concentrations were not significantly different in the two groups, nor were loss of skin-fold thickness and mid-arm muscle circumference. The patients randomized to maintenance fluids lost more weight than those patients on TPN (4.7 vs 2.6 kg, Po0.001). The two groups did not differ with respect to time to engraftment or survival at 200 days. The authors concluded that their group's less aggressive approach to nutritional therapy (patients received 80% of estimated basal energy expenditure as opposed to an average of 130% in the Weisdorf study) may have limited the benefits of TPN. The investigators recommended that TPN be used cautiously in HSCT patients given the greater incidence of fluid overload and sepsis in their study.
Roberts et al 17 randomized 55 breast cancer patients undergoing autograft to receive either prophylactic TPN (N ¼ 27) beginning day À1 or an oral diet (N ¼ 28). Half the group assigned to the oral diet were switched to TPN as a result of poor oral intake for at least 10 days. Use of prophylactic TPN did not improve engraftment (marrow recovery mean day 12.4 in both groups) nor the length of hospital stay (mean 28.7 days in the TPN group compared to mean 25.4 days in the oral diet subjects). Overall survival at 2 years was higher but not of statistical significance in the TPN patients (74 vs 57%) but no differences were detectable by 5 years after transplant. Further, the patients assigned to the oral diet required fewer days of antibiotic therapy (mean 17.7 vs 20.8 days, P ¼ 0.045).
Conclusions derived from reviewed TPN studies
When examining these studies as a group critically, it is a challenging task to construct clinically useful recommendations regarding the use of TPN in HSCT patients. All of the studies reviewed above possess flaws. Most included a small number of study patients and many studied a heterogeneous patient population, including pediatric and adult patients, solid tumors and hematologic malignancies and both allogeneic and autologous transplants. The different disease states required varied conditioning regimens and had very different prognoses with dissimilar risk factors for the development of nutritional depletion. The smaller, more homogenous studies may be too small to detect important clinical outcomes. Many of the older studies did not use hematopoietic growth factor support. Also, nutritional assessment parameters were used inconsistently; further, there are no uniformly accepted clinical outcomes to measure the need and efficacy of TPN. Some studies suggest that the use of TPN may be deleterious. For example, a retrospective study reported by Sheean et al 18 in 48 autologous and allogeneic stem cell recipients noted that use of TPN is strongly associated with hyperglycemia, which may be linked to an increased risk of infection. Because of these limitations, more effective approaches are required for patients receiving HSCT. Over the past 10 years, researchers have been studying the roles of glutamine and lipids in the care of HSCT patients, with mixed results. Newer agents such as palifermin and glucagon-like peptide show promise in minimizing mucositis and enteritis in these patients.
Glutamine (Table 4)
The amino acid glutamine has been shown using animal models to be a constituent amino acid during physiological stress and is a required component of the plasma antioxidant glutathione. [19] [20] [21] Studies in noncancer patients have demonstrated improvements in gut mucosal integrity, nitrogen balance and immunologic function; further, hospitalizations, infectious complications and costs were reduced. [22] [23] [24] [25] Since the early 1990s, researchers have been investigating the efficacy of various formulations of glutamine in HSCT patients.
In 1992, Zeigler et al 26 studied the effects of 0.57 g/kg/day of parenteral glutamine in 45 adult hematologic malignancy patients undergoing allogeneic HSCT. Nitrogen balance was improved in patients who received glutamine (À1.4 vs À4.2 g/day, P ¼ 0.002). Length of hospital stay (29 vs 36 days, P ¼ 0.017), positive blood, stool and throat cultures (variable, all with Po0.05) and clinical infections (three vs nine, P ¼ 0.041) were all reduced in the glutamine group. Conversely, days of antibiotic use, incidence of acute GVHD, time to engraftment, mucositis scores, maximum temperature and extent of blood product support did not differ between the two groups.
Schloerb and Amare 27 performed a double-blind, randomized controlled trial in 29 adult patients with hematologic and solid tumors administering parenteral glutamine supplementation. Allografts receiving standard TPN had a higher incidence of positive blood cultures than those subjects given glutamine supplemented TPN (33 vs 0% positive cultures, Po0.05). Patients who were randomized to the glutamine arm also had shorter lengths of hospital stays (26.9 vs 32.7 days, Po0.05). TPN use, clinical infections, antibiotic use, days of fever, mucositis scores and time to engraftment, however, did not differ between the two groups.
Anderson et al
28 studied enteral glutamine at a dose of 4.0 g/m 2 /day vs placebo in 87 autologous and 106 allogeneic hematologic and solid tumor transplant patients. Autologous transplant patients who received glutamine had less mouth pain and less opioid use (5.0 vs 10.3 days, P ¼ 0.005). Matched sibling donor recipients given glutamine had more days of opiate use (23.2 vs 16.3 days, P ¼ 0.002) while unrelated donor recipients showed no difference in mouth pain or opiate use. These differences were thought to reflect glutamine interactions with methotrexate administration, resulting in higher concentrations and subsequent oral mucosal damage. Composite survival at 28 days was greater in patients randomized to glutamine but survival at 100 days did not differ statistically. Further, TPN use, antibiotic use, acute or chronic GVHD or days of hospitalization did not differ in any transplant type.
Pytlı´k et al 29 reported a comparison of parenteral glutamine 20 g/day or placebo in 40 patients undergoing autologous HSCT for hematologic and solid tumors or autoimmune disorders. Patients assigned to receive glutamine had fewer days of diarrhea (3.3 vs 4.3 days, P ¼ 0.03). Parenteral glutamine therapy, however, increased relapse rates (relapse-free survival P ¼ 0.02), was associated with higher mortality rates (P ¼ 0.05), more severe mucositis, more days of opioid use (3.5 vs 1.2 days, P ¼ 0.04) and higher costs of care (P ¼ 0.002). There were no differences in clinical infection rates, oral intake, and days of fever, antibiotic use, length of stay or times to engraftment.
Canovas et al 30 evaluated GI toxicity, serum glutamine levels, serum protein levels and recovery of neutrophil count in autograft patients randomized to placebo, oral glutamine 20 g/day or an oral whole protein solution. There were no differences between the three groups in any outcomes measured. Coughlin Dickson et al 31 performed a prospective, randomized, double-blinded study in 58 autologous and allogeneic HSCT recipients assigned to receive oral glutamine 30 g/day or placebo. Days of TPN use, length of hospital stay, mucositis severity, time to engraftment, survival, relapse, and severity and days of diarrhea did not differ, although patients received only 0.27 g/kg/day of glutamine, which is less than the accepted safe dose of 0.57 g/kg/day.
Schloerb and Skikne 32 studied 66 hematologic and solid tumor patients undergoing allogeneic and autologous HSCT. All patients randomized to the glutamine arm received oral glutamine 30 g/day; if those patients required TPN, parenteral glutamine was given in place of oral. There were no differences between the glutamine and control groups with respect to length of hospital stay, TPN use, and time to engraftment, positive blood cultures, sepsis, mucositis, GVHD and diarrhea.
Preliminary conclusions regarding glutamine supplementation
The above data are difficult to interpret. Use of oral glutamine showed no benefit on reducing the incidence and severity of mucositis and diarrhea, nor was there improvement in patient survival. Administration of parenteral glutamine in allografts decreased length of hospital stay and rate of infectious complications in some studies but had no effect on mucositis or survival. Paradoxically, and for unclear reasons, parenteral glutamine appeared to be associated with worsened survival in autografts and in allografts receiving methotrexate prophylaxis, resulted in increased mucositis incidence, severity and duration. As a result, parenteral glutamine cannot be recommended as routine supportive care in HSCT patients.
Lipids
The use of lipids in TPN is considered necessary to prevent essential fatty acid deficiency in patients undergoing HSCT. Lipids may also be used to minimize the hyperglycemia that can occur in HSCT patients who have sepsis, diabetes mellitus or GVHD with concomitant corticosteroid use. 33 While there is concern that lipids may cause immunosuppression and an increased incidence of infection as shown by some animal models, studies in HSCT, recipients have not demonstrated this finding. 34 Lipids may also play a role in decreasing the incidence of acute or chronic GVHD by altering the immunologic responses of prostaglandins and leukotrienes. Lenssen et al 35 compared the rates of bacteremia and fungemia in autologous and allogeneic HSCT receiving 6-8% (low dose) or 25-30% (standard dose) of total energy as a 20% lipid emulsion. There were no treatment related differences in incidence or time to first infection and acute or chronic GVHD rates. While the investigators did not comment on the incidence of hypertriglyceridemia, no patients developed essential fatty acid deficiency. Although there was no benefit in providing a higher dose of lipids to the population studied, it appeared to be safe if required to control hyperglycemia.
Muscaritoli et al 36 compared an 80% lipid-based TPN to a 100% glucose-based formula in 60 allogeneic HSCT recipients and showed a similar incidence of acute GVHD. Five patients in the control group, however, died of acute GVHD compared to none in the lipid-based group, possibly due to improved activity of immunosuppressive therapy with a higher lipid dose. Santos and co-workers, 37 however, showed no effect on cyclosporine pharmacokinetics between lipid-enriched (30%) and lipid-free TPN when given to 10 allogeneic HSCT patients.
Lipids appear safe in the HSCT patient population without an increased risk of bacteremia or fungemia, and their effects on GVHD will require further studies.
Palifermin and glucagon-like peptide
In recent years, research has focused less on simply maintaining an adequate nutritional state during transplantation and more on specific substrates that could minimize gastrointestinal toxicity such as palifermin and glucagon-like peptide. In a recent multicenter, placebocontrolled, double-blind, randomized phase three clinical trial, Spielberger et al 38 demonstrated the efficacy of palifermin, a recombinant human keratinocyte growth factor, in reducing the incidence, duration and severity of oral mucositis in autologous HSCT patients. The patients randomized to the palifermin arm had a lower incidence of febrile neutropenia, used less opioid analgesics, had less subjective complaints of mouth pain and required fewer days of TPN. Further multi-center, randomized, placebocontrolled trials are necessary to corroborate this study, and expanding the patient population to include allogeneic HSCT recipients is desirable.
A glucagon-like peptide 2 (GLP-2) analog known as ALX-0600 shows promise in preventing gut mucosal atrophy in patients undergoing chemotherapy. Thought to decrease mucosal apoptosis and increase crypt cell production, GLP-2 has been shown, in several animal models, to increase gut mucosal growth, decrease breakdown of gut mucosa and decrease mucosal permeability in a variety of pathologic intestinal processes. 39 
Future directions
For patients undergoing HSCT, the best nutritional support remains a mystery, and based on data currently available, we cannot recommend that TPN be used uniformly as prophylaxis against nutritional depletion in HSCT recipients. Iestra et al 40 concluded that TPN is not universally required for all transplant patients and cited their data in which 37% of lymphoma autografts met their criteria for needing TPN (severe malnutrition at admission, prolonged period of minimal oral intake and clinical weight loss 410%) compared to 92% of mismatched allografts. Future studies incorporating many aspects of TPN support are necessary (Table 5 ). This approach should be conducted through a large, multicenter, randomized, controlled trial comparing patients with similar diagnostic and prognostic profiles. Glutamine deserves further cautious study to elucidate its interactions with methotrexate and to study its effects on autologous HSCT patients. TPN also needs to be studied along with the use of growth factor support, appetite stimulants and newer agents such as palifermin and glucagon-like peptide. 
